Lv41
450 积分 2022-08-02 加入
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
4小时前
待确认
460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
27天前
已关闭
ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers
27天前
已完结
Upregulation of vesicle-associated membrane protein 7 in breast cancer tissues
1个月前
已完结
Preferential overexpression of glutaredoxin3 in human colon and lung carcinoma
1个月前
已完结
IRF4 as a molecular biomarker in pan-cancer through multiple omics integrative analysis
1个月前
已关闭
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
4个月前
已完结
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations
1年前
已完结
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
1年前
已完结
Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma
1年前
已完结
皖公网安备34019202002308
